With the growing volume of biosimilar and pharma litigation in district courts and before the PTAB, the U.S. International Trade Commission may emerge as another forum for patent holders against imported biosimilars. Section 337 of […]
We post frequently about IPRs here on the blog, because they are an efficient and relatively quick way to get a decision on validity of the patents that cover drugs, biologic or otherwise. In Merck & […]
Law360 has published an article by contributing editors here at Big Molecule Watch. The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming from inter partes
announced today the release of its 2016 BPCIA Litigation Update
and Thinking of Investing In a Biosimilars Product?
The 2016 BPCIA Litigation Update
recaps a busy year in the legal world of biosimilars, […]
Goodwin and the Big Molecule Watch team are looking forward to participating in the 35th Annual J.P. Morgan Healthcare Conference, which brings together leaders from across the industry. If you will be in San Francisco […]